MetrioPharm has released its annual report 2021. The company has provided an overview of the previous year’s achievements, the current state, and gives an outlook on the future business strategy. Thomas Christély, MetrioPharm’s CEO since last October, mentions in his preface that the company was able to increase its equity by a total of CHF 27.5 million in 2021.
Moreover, a clinical phase-II trial with MetrioPharm’s lead compound MP1032 in the treatment of COVID-19 patients, was initiated swiftly in 2021, with the first patient dosed in October. The initiation of the trial corresponded with a research mandate granted by the European Commission. The mandate guarantees considerable revenues supporting said phase-II trial in COVID-19.
Looking ahead, MetrioPharm will be focusing on the systemic examination of so-called Fixed-Dose Combination Therapies in other indication areas, where the current standard therapies show significant side effects. The goal is to combine the individual drugs of these standard therapies at lower doses with MP1032 in a single tablet, thereby producing novel medications with improved efficacy and fewer side effects. MetrioPharm has filed new patent applications for various such Fixed-Dose Combinations in recent months.
Please follow the link to MetrioPharm’s website for a download of the annual report.
